This page contains a Flash digital edition of a book.
Gastrointestinal Cancer


median survivals of 19–25 months and five-year survivals of 19–28%, which compare well with post-operative therapy.115,142,143,149,151,154–158 However, there is a potential bias introduced by the selection process. Randomised controlled trials proving an overall benefit of neoadjuvant therapy are lacking and the risk of missing a resectable tumour due to growth during the treatment period has been proposed. A further question is whether extensive neoadjuvant therapy may actually cause downstaging, as has been claimed in some studies.156,157,159,160


Further comparative studies between


neoadjuvant and adjuvant therapy are needed. Future Aspects


The improvement in post-operative morbidity and mortality due to better surgical technique and improved peri-operative management is expected to continue. One of the major factors is the early treatment of post-operative complications by a dedicated multiprofessional team (surgeon, anaesthesiologist, gastroenterologist, radiologist and specialised nurses). Substantial improvements in long-term survival


1. Gudjonsson B, Cancer of the pancreas. 50 years of surgery, Cancer, 1987;60:2284–2303.


2. Carpelan-Holmström M, Nordling S, Pukkala E, et al., Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry, Gut, 2005;54:385–7.


3. Hedberg M, Borgström A, Genell S, Janzon L, Survival following pancreatic carcinoma: a follow-up study of all cases recorded in Malmö, Sweden, 1977–1991, Br J Surg, 1998;85:1641–4.


4. Bramhall SR, Allum WH, Jones AG, et al., Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study, Br J Surg, 1995;82:111–5.


5. Sener SF, Fremgen A, Menck HR, Winchester DP, Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database, J Am Coll Surg, 1999;189:1–7.


6. Andrén-Sandberg A, Neoptolemos JP, Resection for pancreatic cancer in the new millennium, Pancreatology, 2002;2:431–9.


7. Whipple AO, The rationale of radical surgery for cancer of the pancreas and ampullary region, Ann Surg, 1941;114:612–5.


8. Beger HG, Gansauge F, Master of surgery in Archiv für Klinische Chirurgie, Langenbecks Arch Surg, 2010;395(Suppl. 1): 17–21.


9. Crile G Jr, The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma, Surg Gynecol Obstet, 1970;130:1049–53.


10. Shapiro TM, Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs Whipple resection in good risk patients, Ann Surg, 1975;182:715–21.


11. Howard JM, Pancreatico-duodenectomy: forty-one consecutive Whipple resections without an operative mortality, Ann Surg, 1968;168:629–40.


12. Trede M, Schwall G, Saeger HD, Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality, Ann Surg, 1990;211:447–58.


13. Nitecki SS, Sarr MG, Colby TV, van Heerden JA, Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?, Ann Surg, 1995;221:59–66.


14. Fernandez-del Castillo C, Rattner DW, Warshaw AL, Standards for pancreatic resection in the 1990s, Arch Surg, 1995;130:295–9, discussion 299–300.


15. Delcore R, Rodriguez FJ, Forster J, et al., Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection, Am J Surg, 1996;172:463–8, discussion 468–9.


16. Conlon KC, Klimstra DS, Brennan MF, Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors, Ann Surg, 1996;223:273–9.


17. Gouma DJ, van Geenen RC, van Gulik TM, et al., Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume, Ann Surg, 2000;232:786–95.


18. Balcom JH 4th, Rattner DW, Warshaw AL, et al., Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization, Arch Surg, 2001;136:391–8.


19. Yeo CJ, Cameron JL, Lillemoe KD, et al., Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality, Ann Surg, 2002;236:355–66.


20. Richter A, Niedergethmann M, Sturm JW, et al., Long-term


cannot be expected without better (more effective, less toxic) adjuvant and neoadjuvant therapies. On the other hand, when better adjuvant therapy appears, further refinement of the surgical techniques may become rewarding. Better oncological therapy may make more extensive procedures as well as treatment of patients with advanced disease worthwhile. The possibility of using pre-operative oncological regimens as neoadjuvant or downstaging therapy needs to be further studied, and relevant comparisons with post-operative adjuvant therapy should be performed.


In recent years, the pharmacological and endoscopic palliation of unresectable pancreatic cancer in particular has been an area of much development. However, more research is needed in this field. Specifically, the role of palliative resection of pancreatic cancer could be investigated further.161


A dedicated, multidisciplinary effort around


palliative patients is required; it should be remembered that these patients by far outnumber patients who are resectable with curative intention. n


results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience, World J Surg, 2003;27:324–9.


21. Wagner M, Redaelli C, Lietz M, et al., Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma, Br J Surg, 2004;91:586–94.


22. Schmidt CM, Powell ES, Yiannoutsos CT, et al., Pancreaticoduodenectomy: a 20-year experience in 516 patients, Arch Surg, 2004;139:718–25.


23. Jarufe NP, Coldham C, Mayer AD, et al., Favourable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region, Dig Surg, 2004;21:202–9.


24. Winter JM, Cameron JL, Campbell KA, et al., 1423 pancreaticoduodenectomies for pancreatic cancer: A single- institution experience, J Gastrointest Surg, 2006;10:1199–1210.


25. Pedrazzoli S, Beger HG, Obertop H, et al., A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer, Dig Surg, 1999;16:337–45.


26. Whipple AO, Parsons WB, Mullins CR, Treatment of carcinoma of the ampulla of Vater, Ann Surg, 1935;102:763–9.


27. Hariharan D, Constantinides VA, Froeling FE, et al., The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers – a meta-analysis, Eur J Surg Oncol, 2010;36(10):941–8.


28. Warshaw AL, Thayer SP, Pancreaticoduodenectomy, J Gastrointest Surg, 2004;8:733–41.


29. Haddad LB, Scatton O, Randone B, et al., Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice, HPB (Oxford), 2009;11:203–9.


30. Yeo CJ, Cameron JL, Lillemoe KD, et al.,


Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients, Ann Surg, 1995;221:721–33.


31. Bassi C, Falconi M, Salvia R, et al., Management of complications after ancreaticoduodenectomy in a high volume center: results on 150 consecutive patients, Dig Surg, 2001;18:453–7.


32. Yeo CJ, Cameron JL, Sohn TA, et al., Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes, Ann Surg, 1997;226:248–57.


33. Lin JW, Cameron JL, Yeo CJ, et al., Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula, J Gastrointest Surg, 2004;8: 951–9.


34. Munoz-Bongrand N, Sauvanet A, Denys A, et al., Conservative management of pancreatic fistula after pancreaticoduodenectomy with pancreaticogastrostomy, J Am Coll Surg, 2004;199:198–203.


35. Sarr MG; Pancreatic Surgery Group, The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebocontrolled trial, J Am Coll Surg, 2003;196:556–65.


36. Buchler MW, Friess H, Wagner M, et al., Pancreatic fistula after pancreatic head resection, Br J Surg, 2000;87:883–9.


37. Grobmyer SR, Rivadeneira DE, Goodman CA, et al., Pancreatic anastomotic failure after pancreaticoduodenectomy, Am J Surg, 2000;180:117–20.


38. Z’graggen K, Uhl W, Friess H, Büchler MW, How to do a safe pancreatic anastomosis, J Hepatobiliary Pancreat Surg, 2002;9:733–7.


39. Peng SY, Wang JW, Li JT, et al., Binding pancreaticojejunostomy – a safe and reliable anastomosis


procedure, HPB (Oxford), 2004;6:154–60.


40. Poon RT, Fan ST, Lo CM, et al., External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial, Ann Surg, 2007;246:425–33.


41. Kamoda Y, Fujino Y, Matsumoto I, et al., Usefulness of performing a pancreaticojejunostomy with an internal stent after a pancreatoduodenectomy, Surg Today, 2008;38:524–8.


42. Büchler MW, Friess H, Wagner M, et al., Pancreatic fistula after pancreatic head resection, Br J Surg, 2000;87:883–9.


43. Yekebas EF, Wolfram L, Cataldegirmen G, et al., Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections, Ann Surg, 2007;246:269–80.


44. Doi R, Imamura M, Hosotani R, et al.; Japan Pancreatic Cancer Study Group, Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial, Surg Today, 2008;38:1021–8.


45. Geer RJ, Brennan MF, Prognostic indicators for survival after resection of pancreatic adenocarcinoma, Am J Surg, 1993;165:68–72.


46. Allema JH, Reinders ME, van Gulik TM, et al., Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region, Cancer, 1995;75:2069–76.


47. Kuhlmann KF, de Castro SM, Wesseling JG, et al., Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients, Eur J Cancer, 2004;40:549–58.


48. Howard TJ, Krug JE, Yu J, et al., A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer, J Gastrointest Surg, 2006;10: 1338–45.


49. Raut CP, Tseng JF, Sun CC, et al., Impact of resection status on pattern of failure and survival after


pancreaticoduodenectomy for pancreatic adenocarcinoma, Ann Surg, 2007;246:52–60.


50. Finlayson E, Fan Z, Birkmeyer JD, Outcomes in octogenarians undergoing high-risk cancer operation: a national study, J Am Coll Surg, 2007;205:729–34.


51. Birkmeyer JD, Sun Y, Wong SL, Stukel TA, Hospital volume and late survival after cancer surgery, Ann Surg, 2007;245:777–83.


52. Sohn TA, Yeo CJ, Cameron JL, et al., Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators, J Gastrointest Surg, 2000;4:567–79.


53. Neoptolemos JP, Stocken DD, Dunn JA, et al.; European Study Group for Pancreatic Cancer, Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial, Ann Surg, 2001;234: 758–68.


54. Butturini G, Stocken DD, Wente MN, et al.; Pancreatic Cancer Meta-Analysis Group, Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials, Arch Surg, 2008;143:75–83.


55. Birkmeyer JD, Warshaw AL, Finlayson SR, et al., Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy, Surgery, 1999;125:250–6.


56. Birkmeyer JD, Warshaw AL, Finlayson SR, et al., Relationship between hospital volume and late survival after pancreaticoduodenectomy, Surgery, 1999;126:178–83.


57. Birkmeyer JD, Stukel TA, Siewers AE, et al., Surgeon volume


40


EUROPEAN ONCOLOGY & HAEMATOLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92